DBV Technologies: in demand after NEJM article
(CercleFinance.com) - DBV Technologies are jumping over 10% today, in demand after the New England Journal of Medicine (NEJM) published data from the phase 3 EPITOPE study evaluating its Viaskin Peanut in children aged one to three.
These results showed that epicutaneous immunotherapy (EPIT) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the dose of peanut triggering allergic symptoms.
There are currently no approved treatment options for peanut-allergic children under four years of age, DBV said, which is advancing regulatory efforts in one- to three-year-olds with a confirmed allergy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
These results showed that epicutaneous immunotherapy (EPIT) with Viaskin Peanut was statistically superior to placebo in desensitizing children to peanut by increasing the dose of peanut triggering allergic symptoms.
There are currently no approved treatment options for peanut-allergic children under four years of age, DBV said, which is advancing regulatory efforts in one- to three-year-olds with a confirmed allergy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.